论文部分内容阅读
目的观察生长抑素在急性胰腺炎治疗中的临床疗效。方法 66例急性胰腺炎患者,随机分为观察组和对照组,各33例。对照组患者给予禁食、胃肠减压、抑制胃酸分泌、维持水电解质酸碱失衡、防治感染与器官功能衰竭、吸氧、支持及对症等常规综合治疗;观察组患者在对照组患者治疗基础上给予生长抑素治疗。观察两组患者临床疗效的差异。结果观察组患者腹痛消失时间(51.2±14.4)h、腹部深压痛消失时间(107.8±41.2)h、临床治愈时间(15.6±5.8)d,均优于对照组的(76.4±15.8)h、(152.6±48.4)h、(21.3±5.1)d,差异均具有统计学意义(P<0.05)。观察组治疗总有效率96.97%高于对照组的81.82%,差异具有统计学意义(P<0.05)。两组患者不良反应均轻微,未见明显不良反应。结论在临床治疗急性胰腺炎时加用生长抑素疗效满意,不良反应轻微,值得临床治疗中推广应用。
Objective To observe the clinical effect of somatostatin in the treatment of acute pancreatitis. Methods Sixty-six patients with acute pancreatitis were randomly divided into observation group and control group, with 33 cases in each group. Control group patients given fasting, gastrointestinal decompression, inhibition of gastric acid secretion, maintain water and electrolyte acid-base imbalance, prevention and treatment of infection and organ failure, oxygen, support and symptomatic and other conventional comprehensive treatment; observation group patients in the control group patients treatment basis On the somatostatin treatment. To observe the difference between the two groups of patients with clinical efficacy. Results The disappearance time of abdominal pain (51.2 ± 14.4 h) and the disappearance of deep abdominal pain (107.8 ± 41.2 h) and the clinical cure time (15.6 ± 5.8 d) in observation group were significantly better than those in control group (76.4 ± 15.8 h) and 152.6 ± 48.4) h and (21.3 ± 5.1) d, respectively. All the differences were statistically significant (P <0.05). The total effective rate of observation group was 96.97% higher than 81.82% of control group, the difference was statistically significant (P <0.05). Adverse reactions in both groups were mild, no significant adverse reactions. Conclusions In the clinical treatment of acute pancreatitis plus somatostatin with satisfactory results, minor adverse reactions, it is worth promoting the application of clinical treatment.